4.7 Article

Boosting lung accumulation of gallium with inhalable nano-embedded microparticles for the treatment of bacterial pneumonia

期刊

出版社

ELSEVIER
DOI: 10.1016/j.ijpharm.2022.122400

关键词

Lung delivery; Nanoparticles; Gallium; Drug repurposing; Pseudomonas aeruginosa; Cystic fibrosis

资金

  1. Italian Cystic Fibrosis Research Foundation
  2. [21/2015]

向作者/读者索取更多资源

Recent studies have demonstrated the potential of intra-venous gallium nitrate and direct lung delivery of Ga(III) against Pseudomonas aeruginosa pneumonia. A specially engineered drug delivery system for Ga(III) inhalation is crucial for enhancing its accumulation in the lungs. Ga_HA/CS NPs and Ga_Man NEM, designed to overcome mucus and biofilm surrounding bacteria, show promise in improving therapeutic efficacy through inhalation route.
The potential of intra-venous gallium nitrate (GaN) administration against Pseudomonas aeruginosa pneumonia was recently demonstrated in mice and in cystic fibrosis (CF) patients. Likewise, the added value of direct lung delivery of Ga(III) has been shown in rats. Therefore, the design of a drug delivery system specifically engineered for Ga(III) inhalation is imperative to improve its accumulation in lungs. To this purpose, Ga(III) was efficiently encapsulated into hyaluronic acid/chitosan nanoparticles (Ga_HA/CS NPs), whose features were tuned to facilitate access to the target by overcoming mucus and biofilm surrounding bacteria. Then, to improve in vivo lung deposition, Ga_HA/CS NPs were engineered into mannitol-based NEM (Ga_Man NEM). The powders showed optimal in vitro aerosol performance, and sustained release kinetics in lung lining fluids. Moreover, good tolerability and antimicrobial properties were shown in vitro. Intratracheal insufflation of Ga_Man NEM in rats resulted in a significant improvement of Ga(III) persistence in the lungs coupled to a lower Ga(III) concentration in plasma and urine, compared to GaN solution. Noteworthy, the developed formulation significantly modifies the unfavorable Ga(III) kinetic increasing the Ga(III) to the lung and preventing Ga(III) accumulation in the kidney, key responsible for adverse effects, conclusively demonstrating the benefit of Ga_Man NEM to exploit the therapeutic effect of Ga(III) via inhalation route.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据